Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 32.00 | |
2 mg | In stock | $ 45.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 90.00 | |
25 mg | In stock | $ 162.00 | |
50 mg | In stock | $ 270.00 | |
100 mg | In stock | $ 468.00 | |
500 mg | In stock | $ 1,070.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 90.00 |
Description | Ledipasvir (GS-5885) is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor. |
Targets&IC50 | NS5A(1b replicon):4 pM(EC50), NS5A(1a replicon):34 pM(EC50) |
In vitro | Ledipasvir has GT1a and 1b EC50 values of 31 and 4 pM, respectively, and protein-adjusted EC50 values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC50 of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay[1]. Ledipasvir exhibits an EC50 value of 141 nM against the JFH/3a-NS5A replicon[2]. |
In vivo | Ledipasvir is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey as well as low predicted clearance in human. The pharmacokinetics of Ledipasvir is measured in rats and dogs. Ledipasvir exhibits good half-lives (rat 1.83 ± 0.22 hr, dog 2.63 ± 0.18 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume[1]. |
Synonyms | GS-5885 |
Molecular Weight | 889 |
Formula | C49H54F2N8O6 |
CAS No. | 1256388-51-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (104.6 mM)
Ethanol: 93 mg/mL (104.6 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ledipasvir 1256388-51-8 Microbiology/Virology Proteases/Proteasome HCV Protease SARS-CoV inhibit HCV Inhibitor SARS coronavirus GS-5885 GS 5885 GS5885 Hepatitis C virus inhibitor